Dr Reddy’s Swallows Up Mayne’s US Generics Portfolio For $90m+
Indian Firm Strikes Deal For US Prescription Interests Of Australian Player
Executive Summary
Dr Reddy’s has struck a deal to pay at least $90m for the US prescription generics portfolio of Mayne Pharma. The transaction covers products including Mayne’s recently-launched rival to NuvaRing.
You may also be interested in...
Gloomy First Half Results For Mayne
Revenue falls 33% over the half year for the ailing Australian pharmaceutical as it pivots from generics to the branded market
Dr Reddy’s CEO Sees Strength Through Diversity
With Dr Reddy’s organization now spanning a range of innovative interests and CDMO activities as well as the firm’s traditional small-molecule generics and burgeoning biosimilars businesses, CEO Erez Israeli talked to Generics Bulletin about how these various areas were complementary thanks to the Indian giant’s ‘two-horizon’ approach.
Mayne And Mithra Add Further US NuvaRing Rival
Mayne Pharma and partner Mithra have announced the launch of their Haloette generic version of NuvaRing in the US, adding further competition to a field that already includes Amneal and Teva as well as Prasco’s authorized generic.